For $25 a month you get five (5!) WeedWeek stickers, discounts to all future WeedWeek events, a postcard from Los Angeles, cannabis capital of the world and you get to join a monthly Google hangout with me and other WeedWeek supporters to discuss the latest news…
Brandbuilding opportunities to appear in the newsletter with your links and social media handles start at only $50 a month.
WeedWeek has introduced a new feature called WeedWeek Forum, the cannabis world’s Op-Ed page. Many of you are are eager to share your thoughts and expertise. Here’s your chance to publish on the WeedWeek site.
WeedWeek publishes 400-600 word essays, arguments, observations and fact-based criticisms by outside contributors. We do not accept payment for publishing work.
In an L.A. Times, Op-Ed, net neutrality supporter and FCC member Jessica Rosenworcel (D) writes:
“Net neutrality is the right to go where you want and do what you want on the internet without your broadband provider getting in the way. It means your broadband provider can’t block websites, throttle services or charge you premiums if you want to reach certain online content.”
The end of net neutrality could also make life more difficult for a federally illegal industry like cannabis.
To learn more about net neutrality and what you can do to preserve it, Go to Battleforthenet.com.
Here’s the news.
Rob Kampia, a longtime leader of the legalization movement, is stepping aside as director of Marijuana Policy Project (MPP), which he co-founded in 1995. He will transition into a newly created strategic role.
Leafly’s Bruce Barcott asks whether past sexual harassment allegations explain Kampia’s abrupt move. A 2010 article in Washington (D.C.) City Paper headlined “The Breast Massage Will Happen” enumerated complaints of suggestive behavior several weeks after he had taken a leave of absence for therapy.
“I just think I’m hypersexualized,” Kampia told the Washington Post at the time. Since the 2010 City Paper article, “there have been no allegations of inappropriate behavior against Rob or anyone else at MPP that I’m aware of.” a MPP spokesperson wrote to Leafly.
Colorado’s new rules, including a path to create public-private MED research partnerships, take effect January 1.
A Los Angeles City Council committee approved rules on licensing, operations and other topics. Following industry concerns, the rules would allow provisional licenses for existing growers and manufacturers during the licensing period.
Privateer Holdings, parent company of web site Leafly, cannabis brand Marley Natural and Canadian MED producer Tilray, announced some layoffs, a few weeks after Leafly laid off 13 percent of its staff.
Privateer also called a lawsuit filed against the company by Master P “nonsense.” The suit alleges Privateer backed out of an agreement to distribute the rapper’s cannabis brand.
Ousted MassRoots CEO Isaac Dietrich is waging a proxy fight to remove three of the company’s directors — including Tripp Keber, CEO of edibles company Dixie, and Ean Seeb, co-founder of consulting firm Denver Relief — and the interim CEO. Dietrich, 25, remains the company’s largest shareholder. Dietrich told the Cannabist that he was “extorted based upon false and misleading information into giving up the company.”
Civilized suggests the industry is becoming less friendly to female executives, a phenomenon known as the “grass ceiling.” “Nobody cared when the dispensaries owned by the women in Colorado who started this industry were worth $2 million,” Wanda James, the first black dispensary owner in Colorado said. “But now that they’re 15- or 20-million dollar companies, a lot of the board members – i.e. men – are saying, ‘You can’t handle it from here on in.”
A study presented at the American Heart Association’s Scientific Sessions found heart failure patients who used cannabis were less likely to die in the hospital than abstainers. The researchers had hypothesized the opposite. The study has not yet been peer-reviewed.
The DEA is finalizing schedule II status for a synthetic THC drug called Syndros. The drug was developed by Arizona pharmaceutical firm Insys Therapeutics which opposed REC in the state. Last month, Insys’ billionaire founder John Kapoor was charged with racketeering and fraud related to the company’s marketing of a fentanyl oral spray.